Anthracycline dose intensification improves molecular response and outcome of patients treated for core binding factor acute myeloid leukemia

Haematologica

Volumn 99, Issue 10, 2014, Pages e185-e187

  Prebet, Thomas ^a   Bertoli, Sarah ^b   Delaunay, Jacques ^c   Pigneux, Arnaud ^d   Delabesse, Eric ^e   Mozziconacci, Marie Joelle ^a   Bidet, Audrey ^d   Recher, Christian ^b   Vey, Norbert ^a,f  

^a INSTITUT PAOLI CALMETTES   (France)

^b Institut Universitaire du Cancer de Toulouse Oncopole   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d HAUT LÉVÊQUE HOSPITAL   (France)

^e CHU PURPAN   (France)

^f AIX MARSEILLE UNIVERSITY   (France)

Author keywords

AML; CBF; Daunorubicin intensification

Indexed keywords

CORE BINDING FACTOR; CYTARABINE; DAUNORUBICIN; ANTHRACYCLINE; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOTRANSPLANTATION; CANCER CHEMOTHERAPY; DRUG DOSE COMPARISON; DRUG DOSE INTENSIFICATION; DRUG EFFECT; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE; GENETICS; LEUKEMIA, MYELOID, ACUTE; MORTALITY; REMISSION;

ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; CORE BINDING FACTORS; HUMANS; LEUKEMIA, MYELOID, ACUTE; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84907549612     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.109827     Document Type: Letter

References (14)

1. Lowenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, Ferrant A, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009;361(13):1235-48.
2. Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009;361(13):1249-59.
3. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453-74.
4. Devillier R, Bertoli S, Prebet T, Recher C, Vey N. Induction Therapy For AML Patients With Daunorubicin Dose Of 60 Mg/m² and 90 Mg/m² Results In Similar Complete Response Rate, Relapse-Free and Overall Survival. Blood. 2013;122(21):66.
5. Jourdan E, Boissel N, Chevret S, Delabesse E, Renneville A, Cornillet P, et al. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood. 2013;121(12):2213-23.
6. Yin JA, O'Brien MA, Hills RK, Daly SB, Wheatley K, Burnett AK. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. Blood. 2012;120(14):2826-35.
7. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21(24):4642-9.
8. Breems DA, Van Putten WL, Huijgens PC, Ossenkoppele GJ, Verhoef GE, Verdonck LF, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol. 2005;23(9):1969-78.
9. Byrd JC, Ruppert AS, Mrozek K, Carroll AJ, Edwards CG, Arthur DC, et al. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. J Clin Oncol. 2004;22(6):1087-94.
10. Burnett AK, Hills RK, Milligan D, Kjeldsen L, Kell J, Russell NH, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol. 2011;29(4):369-77.
11. Castaigne S, Pautas C, Terre C, Raffoux E, Bordessoule D, Bastie JN, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012;379(9825):1508-16.
12. Prebet T, Etienne A, Devillier R, Romeo E, Charbonnier A, D'Incan E, et al. Improved outcome of patients with low-and intermediaterisk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine: results of a retrospective comparative study. Cancer. 2011;117(5):974-81.
13. Prebet T, Boissel N, Reutenauer S, Thomas X, Delaunay J, Cahn JY, et al. Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup. J Clin Oncol. 2009;27(28):4747-53.
14. Zhu HH, Zhang XH, Qin YZ, Liu DH, Jiang H, Chen H, et al. MRDdirected risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial. Blood. 2013;121(20):4056-62.